Skip to main content
Erschienen in: memo - Magazine of European Medical Oncology 1/2013

01.02.2013 | editorial

Treatment results for children and adolescents with acute myeloid leukemia in Middle and Eastern European countries

verfasst von: Prof. Dr. med. Ursula Creutzig, PD Dr. med. Gesche Tallen, MD, PhD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Excerpt

Acute myeloid leukemia (AML) corresponds to a heterogeneous group of hematologic neoplasms that originate from bone marrow precursors of the myeloid, monocyte, erythroid, and megakaryocytic cell lineages. While acute lymphoblastic leukemia (ALL) remains the most common childhood malignancy, AML comprises only about 4.8 % of all pediatric cancers in Europe. However, although an orphan disease and despite of remarkable advances during the past decades in both the management and the understanding of the biology and molecular genetics of childhood AML, it still remains one of the most frequent causes of death in children and adolescents with cancer. …
Literatur
1.
Zurück zum Zitat Creutzig U, Van Den Heuvel-Eibrink MM, Gibson B, et al. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood. 2012;120:3187–205.PubMedCrossRef Creutzig U, Van Den Heuvel-Eibrink MM, Gibson B, et al. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood. 2012;120:3187–205.PubMedCrossRef
2.
Zurück zum Zitat Stary J. Long-term results of national treatment trials in childhood acute lymphoblastic leukaemia in several Middle/East European countries. Memo. 2011;4:140–1.CrossRef Stary J. Long-term results of national treatment trials in childhood acute lymphoblastic leukaemia in several Middle/East European countries. Memo. 2011;4:140–1.CrossRef
3.
Zurück zum Zitat Dluzniewska A, Balwierz W, Armata J, et al. Twenty years of Polish experience with three consecutive protocols for treatment of childhood acute myelogenous leukemia. Leukemia. 2005;19:2117–24.PubMedCrossRef Dluzniewska A, Balwierz W, Armata J, et al. Twenty years of Polish experience with three consecutive protocols for treatment of childhood acute myelogenous leukemia. Leukemia. 2005;19:2117–24.PubMedCrossRef
4.
Zurück zum Zitat Reinhardt D, von Neuhoff C, Sander A, et al. Genetic prognostic factors in childhood acute myeloid leukemia. Klin Padiatr. 2012;224:372–6.PubMedCrossRef Reinhardt D, von Neuhoff C, Sander A, et al. Genetic prognostic factors in childhood acute myeloid leukemia. Klin Padiatr. 2012;224:372–6.PubMedCrossRef
5.
Zurück zum Zitat Creutzig U, Ritter J, Budde M, et al. Early deaths due to hemorrhage and leukostasis in childhood acute myelogenous leukemia: Associations with hyperleukocytosis and acute monocytic leukemia. Cancer. 1987;60:3071–9.PubMedCrossRef Creutzig U, Ritter J, Budde M, et al. Early deaths due to hemorrhage and leukostasis in childhood acute myelogenous leukemia: Associations with hyperleukocytosis and acute monocytic leukemia. Cancer. 1987;60:3071–9.PubMedCrossRef
6.
Zurück zum Zitat Creutzig U, Zimmermann M, Reinhardt D, et al. Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98. J Clin Oncol. 2004;22:4384–93.PubMedCrossRef Creutzig U, Zimmermann M, Reinhardt D, et al. Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98. J Clin Oncol. 2004;22:4384–93.PubMedCrossRef
7.
Zurück zum Zitat Creutzig U, Ritter J, Schellong G. Identification of two risk groups in childhood acute myelogenous leukemia after therapy intensification in the study AML-BFM-83 as compared with study AML-BFM-78. Blood. 1990;75:1932–40.PubMed Creutzig U, Ritter J, Schellong G. Identification of two risk groups in childhood acute myelogenous leukemia after therapy intensification in the study AML-BFM-83 as compared with study AML-BFM-78. Blood. 1990;75:1932–40.PubMed
8.
Zurück zum Zitat Creutzig U, Zimmermann M, Ritter J, et al. Definition of a standard-risk group in children with AML. Brit J Haematol. 1999;104:630–9.CrossRef Creutzig U, Zimmermann M, Ritter J, et al. Definition of a standard-risk group in children with AML. Brit J Haematol. 1999;104:630–9.CrossRef
9.
Zurück zum Zitat Creutzig U, Zimmermann M, Lehrnbecher T, et al. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98. J Clin Oncol. 2006;24:4499–506.PubMedCrossRef Creutzig U, Zimmermann M, Lehrnbecher T, et al. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98. J Clin Oncol. 2006;24:4499–506.PubMedCrossRef
10.
Zurück zum Zitat Kaspers GJL, Zimmerman M, Reinhardt D, et al. Improved outcome in pediatric relapsed AML: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group. J Clin Oncol. 2013 (Epub ahead of print). Kaspers GJL, Zimmerman M, Reinhardt D, et al. Improved outcome in pediatric relapsed AML: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group. J Clin Oncol. 2013 (Epub ahead of print).
11.
Zurück zum Zitat Steliarova-Foucher E, Stiller C, Kaatsch P, et al. Geographical patterns and time trends of cancer incidence and survival among children and adolescents in Europe since the 1970s (the ACCISproject): an epidemiological study. Lancet. 2004;364:2097–105.PubMedCrossRef Steliarova-Foucher E, Stiller C, Kaatsch P, et al. Geographical patterns and time trends of cancer incidence and survival among children and adolescents in Europe since the 1970s (the ACCISproject): an epidemiological study. Lancet. 2004;364:2097–105.PubMedCrossRef
12.
Zurück zum Zitat Tallen G, Henze G, Creutzig U, Dworzak M, Klingebiel T. Auswirkungen der EU-Direktive für klinische Studien auf Kinder und Jugendliche mit Krebserkrankungen in Europa. FORUM-DKG. 2010;25:42–8. Tallen G, Henze G, Creutzig U, Dworzak M, Klingebiel T. Auswirkungen der EU-Direktive für klinische Studien auf Kinder und Jugendliche mit Krebserkrankungen in Europa. FORUM-DKG. 2010;25:42–8.
13.
Zurück zum Zitat Kowalczyk J. Current clinical trials: challenges in Central and Eastern Europe. SIOPe News 2008. Kowalczyk J. Current clinical trials: challenges in Central and Eastern Europe. SIOPe News 2008.
14.
Zurück zum Zitat Balwierz W, Pawinska-Wasikowska K, Klekawka T, et al. Development of treatment and clinical results in childhood acute myeloid leukemia in Poland. Memo. 2013;1. doi:10.1007/s12254-012-0061-9. Balwierz W, Pawinska-Wasikowska K, Klekawka T, et al. Development of treatment and clinical results in childhood acute myeloid leukemia in Poland. Memo. 2013;1. doi:10.1007/s12254-012-0061-9.
15.
Zurück zum Zitat Sramkova L, Sterba J, Hrstkova H, et al. Development of treatment and clinical results in childhood acute myeloid leukemia in the Czech Republic. Memo. 2013;1. doi:10.1007/s12254-012-0059-3. Sramkova L, Sterba J, Hrstkova H, et al. Development of treatment and clinical results in childhood acute myeloid leukemia in the Czech Republic. Memo. 2013;1. doi:10.1007/s12254-012-0059-3.
16.
Zurück zum Zitat Szegedi I, Jakab Z, Masath P, et al. Development of treatment and clinical results in childhood acute myeloid leukemia in Hungary. Memo. 2013;1. doi:10.1007/s12254-012-0054-8. Szegedi I, Jakab Z, Masath P, et al. Development of treatment and clinical results in childhood acute myeloid leukemia in Hungary. Memo. 2013;1. doi:10.1007/s12254-012-0054-8.
17.
Zurück zum Zitat Kolenova A, Bubanska E, Oravkinova I, et al. Development of treatment and clinical results in childhood acute myeloid leukemia in the Slovak Republic. Memo. 2013;1. doi:10.1007/s12254-012-0052-x. Kolenova A, Bubanska E, Oravkinova I, et al. Development of treatment and clinical results in childhood acute myeloid leukemia in the Slovak Republic. Memo. 2013;1. doi:10.1007/s12254-012-0052-x.
18.
Zurück zum Zitat Krstovski N, Kuzmanovic M, Vujic D, et al. Treatment results of childhood acute myeloid leukemia in Serbia. Memo. 2013;1. doi:10.1007/s12254-012-0051-y. Krstovski N, Kuzmanovic M, Vujic D, et al. Treatment results of childhood acute myeloid leukemia in Serbia. Memo. 2013;1. doi:10.1007/s12254-012-0051-y.
Metadaten
Titel
Treatment results for children and adolescents with acute myeloid leukemia in Middle and Eastern European countries
verfasst von
Prof. Dr. med. Ursula Creutzig
PD Dr. med. Gesche Tallen, MD, PhD
Publikationsdatum
01.02.2013
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 1/2013
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-013-0070-3

Weitere Artikel der Ausgabe 1/2013

memo - Magazine of European Medical Oncology 1/2013 Zur Ausgabe